Global Onychomycosis Market Industry Analysis, Size, Share and Growth Trends 2020-2026

 

Summary - A new market study, titled “Global Onychomycosis Market Research Report Forecast to 2025” has been featured on WiseGuyReports.

Global Onychomycosis Market: Information by Type (Distal Subungual Onychomycosis (DSO), White Superficial Onychomycosis (WSO), Proximal Subungual Onychomycosis (PSO), Candida Onychomycosis and others), Treatment Type (Drug Treatment, Topical Therapy and others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025

 

Market analysis

Generally, onychomycosis implies to the fungal infection of the nail. The global onychomycosis market is expected to exhibit lucrative growth during the forecast period. Some of the major factors characterizing the market growth are rising global prevalence of onychomycosis, rising per capita healthcare spending, surging diabetic patient population, and increasing prevalence of peripheral artery disease (PAD). The Global Onychomycosis Market is expected to register a CAGR of 6.28% to reach 7,912.5 million by 2025. The aging population, increased ingesting of immunosuppressive drugs, rising prevalence of diseases such as human immunodeficiency virus (HIV) and diabetes that suppress the immune- status of patients, increased experience to spas and public swimming pools, wearing tight-fitting shoes and clogs, and wearing sweaty footwears have been the factors for the rise in the incidence of mycoses. Onychomycosis represents 20% to 40% of all onycho-pathies around the earth. An article published on the ScienceDirect stated that, at present, worldwide onychomycosis prevalence ranges from 2% to 50%, and it represents roughly 30% of superficial mycotic infections and 50% of all nail disorders. Additionally, onychomycosis mainly affects adults between 30 and 60 years of age. Thus, this increasing prevalence of onychomycosis across the world is fueling the necessity for treatment drugs and therapies around the globe, thereby supporting the market growth. In January 2019, Galderma Laboratories revealed the opening of a new office in Malaysia, which would help it to accelerate the growth in the region. On the contrary, the side-effects associated with onychomycosis treatment drugs as well as lack of awareness about onychomycosis are anticipated to limit the market growth over the forecast period. Onychomycosis also called tinea unguium, is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate. An article published in the Journal of Tropical Medicine stated that, presently, the prevalence of onychomycosis mainly caused by nondermatophyte molds is rising around the globe.

Also Read: https://nyheadline.com/press/onychomycosis-2020-global-market-outlookresearchtrends-and-forecast-to-2025/24708

Market segmentation

The Global Onychomycosis Market is segmented based on distal subungual onychomycosis (DSO), white trivial onychomycosis (WSO), proximal subungual onychomycosis (PSO), candida onychomycosis, as well as others. In June 2019, Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of J&J Services announced a partnership with the University of California, Berkeley and the University of California, San Francisco, to enlarge data science research in healthcare Based on conduct type, the global onychomycosis market has been divided into drug treatment, topical treatment, and others. The global onychomycosis market, by distribution channel, has been segmented into hospital pharmacies, retail pharmacies, and others. The retail pharmacies segment held a share of 35.8% in 2018. In November 2018, Moberg Pharma signed an exclusive agreement with Mundipharma to commercialize Emtrix in the Middle East and African region

 

Regional analysis

Geographically the Global Onychomycosis Market is split in regions like North & South America, Europe, Asia-Pacific, Middle east and Africa and Rest of the world. Asia-Pacific is anticipated to be the sharpest-expanding region in the global marketplace owing to the survival of huge older general population, quickly enlarging medical expertise, growing nonrefundable revenue, convenience of drugs, and high unmet clinical needs. India apprehended a share of 12.57% in onychomycosis market in 2018. The Americas is expected to hold the greatest share of the global onychomycosis market. This owes to the authority of key market participants, modern healthcare infrastructure, increasing prevalence of onychomycosis and peripheral artery illness, rising per capita healthcare outflow, and a surge in the diabetic patient population. The onychomycosis market in the Middle East and Africa is expected to witness a modest market growth rate from 2019 to 2025. The Middle East would lead the market growth, attributing to facts such as increasing partnerships or agreements to commercialize onychomycosis goods, developing healthcare infrastructure, booming medical tourism, budding healthcare industry, and growing consciousness about onychomycosis and its treatment drugs and therapies. Europe is also expected to hold a substantial market share in the coming years. This is attributed to the rising geriatric population and escalating burden of diabetes, flourishing pharmaceutical manufacturing, and growing experience rates of onychomycosis in the UK, Germany, France, and Spain.

 

Major players

The proposed spectators in the Global Onychomycosis Market are Pharmaceutical companies, manufacturers, Retailers, distributors, wholesalers, Investors and trade experts, Governments, associations, industrial bodies, etc. The major companies functioning in the Global Onychomycosis Market are concentrating on firming their global ways by entering into untouched markets. The projected onlookers in the Global Onychomycosis Market are companies like Galderma Laboratories (Switzerland ), Novartis AG (Switzerland), Pfizer, Inc. (the US), Taro Pharmaceuticals Industries Ltd (Israel) Bausch Health Sciences (Canada), Moberg Pharma AB (Sweden), Dr. Reddy’s Laboratories Ltd (India), Medimetriks Pharmaceuticals, Inc. (US), Merz Pharma (Germany), Kaken Pharmaceutical Co., Ltd (Japan), Johnson & Johnson Services, Inc. (US) an GlaxoSmithKline plc (UK), among others.

FOR MORE DETAILS:  https://www.wiseguyreports.com/reports/5166730-global-onychomycosis-market-research-report-forecast-to-2025

About Us:

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.               

 

Contact Us:

NORAH TRENT                                                      

sales@wiseguyreports.com      

Ph: +162-825-80070 (US)                         

Ph: +44 203 500 2763 (UK)